#492 I Read All the Human Studies on the Most Popular Peptides - Here's What the Data Shows

Peptides are everywhere right now, with bold promises for recovery, fat loss, and longevity, but most lack solid human data.

I pulled every human trial I could find on the most-hyped compounds to see what actually holds up, and I’m not promoting anything—just looking at the evidence.

Thymosin beta‑4 looks safe and shows some eye benefits in small trials, but there’s no human proof for joint or tendon repair despite strong animal data.

Thymosin alpha‑1 has robust human evidence and is approved in many countries for immune support and as a vaccine adjuvant, though it doesn’t regrow the thymus itself.

BPC‑157 shines in rodents for tendon, muscle, bone, gut, and even spinal injury models, yet there are no completed human trials—plenty of anecdotes, no clinical confirmation.

Epitalon is intriguing for circadian rhythm and melatonin, with Russian human studies suggesting healthspan benefits, but methods and conflicts of interest mean we need replication elsewhere.

MOTS‑c tracks with exercise, metabolism, and insulin sensitivity, rises with intense training, and may blunt myostatin, but it has no human intervention trials yet.

Humanin is linked to healthier aging markers and protects cognition in animal models, with lifespan signals in worms, but human outcome trials are still missing.

Cerebrolysin, a peptide mix used clinically in some countries, delivers short‑term gains in recovery after stroke and traumatic brain injury, without clear long‑term or mortality benefits.

Semax, another Russian brain peptide, likely boosts BDNF and monoamines and can be used intranasally; early human data is local and limited.

CJC‑1295 reliably drives growth hormone and IGF‑1 up for days, though body‑composition outcomes are unclear and it’s prohibited in sport.

MK‑677 increases growth hormone and IGF‑1, adds lean mass in older adults, and improves sleep, but it doesn’t boost strength, often increases hunger and water retention, and is also banned in competition.

Tesamorelin is FDA‑approved for HIV‑related lipodystrophy, consistently cuts visceral fat, and preserves muscle.

IGF‑1 LR3 lacks human trials, while regular IGF‑1 is approved for specific growth disorders, not for anti‑aging or physique goals.

Topical copper peptide GHK improves skin density, collagen, and wrinkle metrics in human cosmetic studies; oral and injectable data in humans are not there yet.

Melanotan II darkens skin and boosts arousal in trials and may blunt UV damage in fair skin, but mole darkening and melanoma case reports mean caution is warranted.

Retatrutide delivers striking weight loss and better metabolic markers in trials and could be the biggest healthspan mover for people with obesity, though it’s not yet approved and data in healthy lean people is absent.

Big picture: some peptides have meaningful human evidence, others have none, and anecdotes are not outcomes.

I’m not advocating use; the largest risk is sourcing—random online products can be impure or mislabeled, so work with a physician and reputable compounding pharmacies if you go there at all.

That’s a lot to digest, so bookmark this for reference, and if you want my take on which over‑the‑counter supplements actually have human data, jump to the next piece.